Can Scientists Restore Gene Activity Without Editing the DNA Sequence?

A 2026 neuroscience breakthrough uses CRISPR activation to restore gene expression and improve cellular abnormalities in human-derived models of autism

Biotech International Institute (BII)

The Next Generation of Precision Neuroscience: Five Discoveries Redefining Brain Research

Thursday, November 19, 2026

Introduction: What If the Problem Is Not a Missing Gene, but an Underactive One?

Every human cell contains an extraordinary set of genetic instructions.

These instructions help regulate development, cellular identity, metabolism, and the formation of biological structures.

In the nervous system, genes contribute to neuronal development, synaptic communication, electrical excitability, and the molecular organization of brain circuits.

But possessing a gene is not enough.

The gene must also be expressed at an appropriate level, in the appropriate cells, at the appropriate time.

Too little expression of a critical gene can disrupt cellular function.

Too much expression can also be harmful.

This creates an important challenge for precision neuroscience.

What happens when a person has one functional copy of an important gene, but the other copy no longer works properly?

Could researchers increase the activity of the remaining functional copy?

And could that restore aspects of normal cellular function without permanently rewriting the DNA sequence?

On November 13, 2026, a study published in Nature Neuroscience provided intriguing evidence that this strategy may be possible in human-derived laboratory models.

Researchers from UCLA and collaborating institutions investigated two genes strongly associated with particular neurodevelopmental conditions: CHD8 and SCN2A.

Using a modified CRISPR system that activates gene expression rather than cutting DNA, the investigators increased expression of the remaining functional gene copies.

They then examined how the intervention affected developing neurons and laboratory-grown cortical organoids.

The findings were significant.

In CHD8-mutant models, the approach improved selected abnormalities involving neural development, gene-expression patterns, and organoid size.

In SCN2A-mutant models, it improved neuronal maturation and substantially restored electrical firing activity.

The findings introduce a new direction for investigating genetically defined neurological conditions.

Rather than replacing an entire gene, researchers may be able to regulate the activity of an existing functional copy.

For Biotech International Institute, this discovery reinforces an essential principle.

Understanding the exact molecular mechanism behind a neurological abnormality may reveal interventions that would otherwise be overlooked.

---

1. Why Gene Expression Matters as Much as DNA Sequence

DNA contains genetic information, but cells do not use every gene continuously.

Different cell populations express different combinations of genes.

For example, a neuron expresses proteins necessary for electrical signaling.

An astrocyte expresses a different collection of molecules that support metabolic regulation and the neuronal environment.

Even within the same cell, gene expression changes over time.

Developmental signals activate some genes and reduce the activity of others.

External conditions can also influence these patterns.

Gene expression therefore acts as a biological control system.

The underlying DNA provides instructions.

Regulatory mechanisms determine how those instructions are used.

The new study investigates whether scientists can influence those regulatory mechanisms to compensate for certain disease-associated genetic deficiencies.

2. What Is Haploinsufficiency?

Most people possess two copies of many genes, one inherited from each biological parent.

In some genetic conditions, one copy loses normal function.

The remaining copy continues producing a functional gene product.

But its activity may not be sufficient to support normal cellular function.

This is called haploinsufficiency.

Imagine a biological system that normally requires a particular level of protein production.

One working gene copy may produce less than the amount needed for typical function.

The problem is not that the protein is completely absent.

The problem is that its quantity may be inadequate.

That creates a potential opportunity.

If scientists can safely increase expression from the remaining functional copy, they may be able to restore part of the missing biological activity.

However, this strategy is not suitable for every genetic mutation.

Some mutations produce harmful proteins rather than simply reducing protein quantity.

Others involve more complex mechanisms.

The approach must be matched to the underlying biology.

3. The November 2026 Discovery

The study was titled:

Enhancer-targeted CRISPR-A rescues haploinsufficiency and mutant phenotypes in organoid models of autism.

The research team was led by George T. Chen, Gayatri Nair, Aubrey J. Osorio, and colleagues, with senior investigator Daniel H. Geschwind.

The researchers examined two high-confidence autism-associated genes:

CHD8, which contributes to the regulation of gene expression and neurological development.

SCN2A, which encodes a voltage-gated sodium-channel protein involved in neuronal electrical signaling.

The team used human pluripotent stem cell-derived neurons and cerebral cortical organoids carrying loss-of-function mutations.

These models allowed the investigators to examine how reduced gene activity affected selected aspects of neural development and function.

They then tested whether enhancer-targeted CRISPR activation could increase gene expression and improve the resulting abnormalities.

The study demonstrated that selected molecular and cellular changes could be partially or substantially rescued, depending on the gene, model, and endpoint.

This was a proof-of-concept experiment, not a human clinical trial.

4. How Is CRISPR Activation Different From Conventional CRISPR Gene Editing?

CRISPR is widely associated with technologies capable of modifying DNA sequences.

Conventional CRISPR-Cas9 systems can use a guide RNA to direct a DNA-cutting enzyme toward a selected genetic location.

The resulting DNA break can be used in certain approaches to alter the sequence.

But CRISPR technology is not limited to cutting DNA.

Researchers have also developed versions that recognize DNA without making a cut.

One approach uses dead Cas9, or dCas9.

Despite its name, dCas9 is a modified Cas9 protein that retains the ability to recognize a targeted DNA location but lacks the normal DNA-cleaving activity.

Researchers can attach regulatory components to dCas9.

These components can increase or decrease the activity of nearby genes.

When the system increases gene expression, it is called CRISPR activation, or CRISPR-A.

The key distinction is that the intervention regulates transcription rather than directly cutting and replacing the DNA sequence.

However, modifying gene expression can still have important biological consequences.

Avoiding DNA cleavage does not automatically establish complete safety.

5. What Are Genetic Enhancers?

The genome contains more than protein-coding genes.

It also contains regulatory regions that influence how genes are expressed.

One important class is called enhancers.

Enhancers are DNA regions that help regulate gene activity, often by interacting with transcriptional machinery and other regulatory proteins.

Their effects can depend on cell type and developmental stage.

An enhancer may be active in developing neurons but less active in other tissues.

This creates an interesting possibility for targeted intervention.

Instead of directly stimulating a gene's promoter in every cell where the gene is present, scientists may target an enhancer that operates in a more restricted biological context.

That could potentially provide greater control over when and where gene expression increases.

The 2026 researchers investigated this approach using regulatory regions associated with CHD8 and SCN2A.

6. Why Target an Enhancer Instead of the Gene's Promoter?

A promoter is a regulatory region near the beginning of a gene that helps initiate transcription.

Targeting a promoter can increase gene expression.

But some genes are highly sensitive to dosage.

Producing too much protein may be as problematic as producing too little.

The researchers reasoned that enhancer targeting could better preserve aspects of normal biological regulation.

Their experiments produced an important observation.

For certain conditions, enhancer-targeted CRISPR activation increased expression in mutant cells without significantly increasing expression in corresponding wild-type cells.

By contrast, promoter-targeted activation could increase expression in both mutant and wild-type cells.

This suggests that enhancer targeting may offer an advantage when precise gene dosage matters.

However, this specificity was demonstrated in the experimental systems used in the study.

It should not be interpreted as proof that enhancer targeting is universally selective or free from unintended effects.

7. Meet CHD8: A Gene Involved in Neural Development

CHD8 encodes chromodomain helicase DNA-binding protein 8.

It participates in chromatin regulation and influences gene-expression programs involved in development.

Certain loss-of-function CHD8 variants are associated with a genetically defined neurodevelopmental condition that can include autistic features and other developmental differences.

Researchers have investigated how reduced CHD8 function influences neural progenitor behavior, neuronal maturation, and brain development.

In the 2026 study, CHD8-mutant cortical organoids displayed abnormalities compared with the relevant control models.

These included altered cellular maturation and increased organoid size.

The investigators then used enhancer-targeted CRISPR activation to increase CHD8 expression.

The results provided an opportunity to investigate whether restoring gene dosage could influence those cellular features.

8. What Happened When Researchers Restored CHD8 Activity?

The results were encouraging within the experimental models.

Increasing CHD8 expression was associated with improvements in several measured abnormalities.

Researchers observed changes in markers of neuronal maturation.

They also found that some treated mutant cortical organoids became smaller, moving toward the sizes observed in control organoids.

Gene-expression analyses showed that treated mutant samples shifted toward patterns associated with the corresponding wild-type models.

This was important because the intervention affected more than one measurement.

It influenced both molecular characteristics and aspects of cellular development.

However, not every result was identical across cell lines or experimental conditions.

The extent of gene activation varied.

Some outcomes showed stronger rescue than others.

The findings therefore support a mechanism worth investigating rather than establishing complete normalization of neurological development.

9. Meet SCN2A: A Gene That Helps Neurons Generate Electrical Signals

SCN2A encodes the voltage-gated sodium-channel protein Naᵥ1.2.

Voltage-gated sodium channels are important components of neuronal electrical signaling.

They help generate and propagate action potentials, the electrical impulses through which neurons communicate.

SCN2A-related disorders can arise through different genetic mechanisms.

Some variants reduce channel function.

Others may produce different functional effects.

Clinical presentations can include developmental differences, epilepsy, and autism-associated features, depending on the specific variant and biological context.

The 2026 study focused on models in which reduced functional SCN2A expression was an important part of the experimental mechanism.

The researchers investigated whether increasing expression of the functional copy could improve neuronal electrical activity.

10. What Happened When Scientists Increased SCN2A Expression?

The investigators used human-derived excitatory neurons carrying SCN2A mutations.

They measured gene expression and neuronal electrical function.

After enhancer-targeted CRISPR activation, SCN2A expression increased in the mutant models.

The researchers also observed improvements in markers associated with neuronal maturation.

Most importantly, they examined electrical firing using electrophysiological recordings.

In selected mutant neuronal lines, the intervention substantially restored the ability to generate action potentials.

Some measurements approached the levels observed in control neurons.

However, the response varied by cell line.

Certain finer electrophysiological properties did not normalize consistently across all the tested models.

This distinction is important.

Restoring a major functional endpoint is a meaningful experimental result, but it does not prove that every aspect of neuronal physiology has returned to normal.

11. Why Electrical Measurements Strengthen the Study

A common limitation in gene-expression research is that an intervention may increase the amount of RNA or protein without improving cellular function.

A molecular measurement can demonstrate that a target has been affected.

But it may not establish that the intervention produces a meaningful biological result.

The SCN2A experiments went further.

Researchers used electrophysiology to measure neuronal behavior directly.

They evaluated action-potential firing under controlled stimulation.

These findings helped connect gene-expression changes with a relevant cellular function.

That connection strengthens the mechanistic evidence.

It demonstrates why neurological research should not rely exclusively on gene-expression biomarkers when direct functional measurements are available.

12. Why the Effects Were Different in Mutant and Healthy Cells

One of the study's most intriguing findings was that enhancer-targeted activation did not significantly increase the target genes in the tested wild-type models.

The mutant models, however, showed increases in CHD8 or SCN2A expression.

This suggests that enhancer-based regulation can respond differently depending on the genetic and cellular context.

For dosage-sensitive genes, such a result could be valuable.

An ideal intervention would restore insufficient activity without unnecessarily increasing expression in cells that already have appropriate levels.

But the mechanism of this context-dependent response requires further investigation.

It cannot be assumed that every enhancer or every mutation will behave similarly.

The selectivity observed in the study provides a promising experimental foundation.

It is not a universal guarantee.

13. Timing Was a Critical Variable

A particularly important finding involved developmental timing.

The researchers found that the effects of enhancer-targeted CRISPR activation depended partly on when the intervention was introduced.

For example, certain CHD8-targeted approaches were more effective at earlier developmental stages.

SCN2A-targeted activation showed different responses depending on the timing of treatment.

This is consistent with the fact that gene regulation changes during neural development.

An enhancer that is active during one developmental period may be less responsive at another.

The implications are substantial.

A method that works in early-stage organoids may not work equally well in mature neurons.

And an intervention effective during a particular developmental window may not produce the same effect later in life.

Researchers will need to determine how developmental timing influences future applications.

14. How Long Did the Effects Last?

The investigators also examined the persistence of increased gene expression.

In selected organoid experiments, enhancer-targeted CRISPR activation produced elevated CHD8 or SCN2A expression across multiple measurements extending over several months.

This was encouraging because it showed that the response was not necessarily restricted to a brief interval immediately after treatment.

However, these experiments used laboratory systems with engineered expression machinery.

A sustained effect in organoids does not demonstrate lifelong gene regulation in a human brain.

It also does not establish how the intervention would behave following different delivery methods.

Duration, reversibility, and long-term safety remain important questions.

15. Why Brain Organoids Were Essential to the Research

Brain organoids are three-dimensional models grown from human-derived stem cells.

They reproduce selected features of neural development and cellular organization.

They are not complete human brains.

But they allow researchers to investigate developmental processes that may be difficult to study directly in people.

In the new study, cortical organoids helped reveal abnormalities involving neuronal maturation, cell populations, and tissue growth.

They also provided a way to examine whether increasing gene expression could improve those features.

The researchers combined organoids with two-dimensional neuron cultures.

This was important because each model contributed different measurements.

Organoids provided information about cellular development within a three-dimensional system.

Neuron cultures offered a useful platform for detailed physiological analysis.

Together, they created a stronger experimental framework than either method alone.

16. Does This Mean Scientists Have Developed an Autism Treatment?

No.

Autism is a heterogeneous neurodevelopmental condition with diverse genetic, developmental, behavioral, and environmental influences.

The study focused on specific gene-related experimental models.

It did not investigate all forms of autism.

It did not treat autistic patients.

It did not demonstrate improvements in human communication, daily functioning, or quality of life.

And it did not establish a safe or effective clinical intervention.

The findings are most directly relevant to understanding whether selected consequences of CHD8 or SCN2A haploinsufficiency can be modified in human-derived laboratory systems.

That is a meaningful scientific achievement.

But it is not evidence that autism as a whole can be corrected by increasing gene activity.

It is also important that future research respects the diversity of autistic people and evaluates potential interventions in relation to clearly defined medical needs and meaningful outcomes.

17. Why This Approach Might Matter Beyond Autism

Haploinsufficiency is not unique to autism-associated conditions.

Other genetic disorders involve situations in which one functional gene copy does not provide sufficient biological activity.

This raises the possibility that enhancer-targeted CRISPR activation could become a broader research strategy.

Scientists may investigate whether suitable regulatory elements exist for additional dosage-sensitive genes.

They may also explore whether restoring gene expression changes measurable cellular abnormalities.

However, several requirements must be met.

The mutation must be appropriate for a gene-activation strategy.

A functional copy must remain available.

The relevant enhancer must be identifiable.

The system must act in the correct cells.

Gene dosage must be controlled.

And meaningful benefits must be demonstrated without unacceptable risks.

Each condition requires a separate mechanistic evaluation.

18. The Main Challenge: Delivering the System Safely

A laboratory experiment can introduce CRISPR activation components into cells under carefully controlled conditions.

Delivering those components into a living human brain is substantially more challenging.

Researchers must determine how to reach appropriate cells.

They must evaluate whether the activation machinery remains functional.

They must consider immune responses and possible unintended effects.

They must also assess how long the intervention remains active.

The study used viral delivery approaches in experimental cellular systems.

Such laboratory methods cannot automatically be assumed to provide suitable clinical delivery.

Even without deliberately cutting DNA, sustained CRISPR activation may influence gene regulation in unintended ways.

Some delivery systems can introduce additional genomic risks.

These issues require thorough evaluation before clinical investigation.

19. The Importance of Off-Target and Gene-Dosage Assessment

One of the principal attractions of CRISPR activation is that it can regulate gene expression without using the standard DNA-cutting function of Cas9.

However, avoiding DNA cleavage does not mean avoiding every potential off-target effect.

A guide RNA could interact with unintended genomic regions.

An activation component could influence nearby regulatory pathways.

Excessive expression of the intended gene could also disrupt normal cellular function.

These concerns are especially important for dosage-sensitive neurological genes.

Researchers therefore need to assess both intended and unintended transcriptional changes.

They must determine whether the intervention acts at appropriate developmental stages.

They should also investigate whether observed benefits persist without producing harmful longer-term effects.

Precision requires more than accurate targeting.

It requires controlled biological consequences.

20. What This Discovery Means for Biotech International Institute

At Biotech International Institute, our primary neurological research programs involve investigational small molecules and separate precision peptide concepts.

The UCLA study did not investigate BII's candidates.

It also does not establish a direct application of CRISPR activation to our current platforms.

However, it provides an important scientific lesson.

A carefully defined molecular mechanism can help researchers identify more appropriate ways to measure and potentially influence neurological function.

For NeuroReset™, our research-stage interests include neural adaptation and post-dependency recovery biology.

The study reinforces the importance of identifying molecular changes that have a functional relationship with neurological outcomes.

But it provides no evidence that NeuroReset™ affects CHD8, SCN2A, or gene-regulatory enhancers.

For Mycophorol™, our fungal-inspired research direction includes hypotheses involving neural resilience and neurotrophic-related signaling.

The new findings demonstrate why gene-expression changes must be connected to meaningful cellular measurements.

They do not establish Mycophorol™ effects on the pathways investigated.

For Neurophorol™, our cannabinoid-inspired research direction focuses on receptor pharmacology and neuroimmune-related hypotheses.

The study illustrates the importance of cellular context and biological selectivity.

It does not demonstrate a direct connection to the proposed CRISPR activation mechanism.

BII's peptide programs are likewise distinct from the gene-activation approach studied here.

The central relevance is methodological, not a claim of comparable activity.

21. What Would Responsible Translational Validation Require?

Future development of a gene-activation intervention would require evidence across several levels.

Genetic mechanism

Is insufficient expression of a functional gene copy a major contributor to the condition being investigated?

Regulatory targeting

Does the selected enhancer provide appropriate control over gene expression?

Cell specificity

Does the system act in the intended cell populations?

Dosage control

Can expression be increased without harmful overactivation?

Functional response

Do molecular changes correct biologically meaningful abnormalities?

Developmental timing

Does the intervention remain effective at a clinically relevant age or developmental stage?

Delivery and safety

Can the required components reach the relevant tissue without unacceptable risks?

Long-term effects

Are the biological changes durable, appropriately regulated, and safe?

Independent replication

Can other laboratories reproduce the central findings?

Clinical relevance

Do the effects eventually translate into outcomes that matter to patients?

These questions define the distance between a promising laboratory mechanism and an established therapeutic technology.

22. What Scientists Still Need to Discover

The November 2026 study opens several important questions.

Can enhancer-targeted CRISPR activation work in additional human cell populations?

How accurately can researchers predict which enhancers regulate specific disease-associated genes?

Why does activation occur more strongly in some mutant cells than in corresponding wild-type models?

Will the effects persist in mature neuronal circuits?

Could gene activation be safely regulated or reversed if necessary?

How can delivery systems reach selected brain-cell populations?

Are there unintended consequences of sustained epigenetic regulation?

Can the observed cellular improvements be reproduced in additional models?

Which genetic variants are appropriate for this strategy?

And can investigators eventually demonstrate meaningful and safe clinical benefits in carefully selected conditions?

Each question requires independent investigation.

Closing Thought: Precision Neuroscience May Be About Adjusting Gene Activity, Not Just Rewriting DNA

The human genome is more than a collection of genetic sequences.

It is also a complex regulatory system.

Genes must be activated at appropriate times.

Their expression must be maintained within suitable ranges.

And their activity must correspond to the needs of individual cell populations.

The November 2026 CRISPR activation study demonstrates a promising experimental approach to these challenges.

Rather than directly replacing a defective gene, the researchers increased expression of a remaining functional copy.

In CHD8-mutant models, that intervention improved aspects of neuronal development and organoid growth.

In SCN2A-mutant models, it improved neuronal maturation and substantially restored selected electrical functions.

The results demonstrate that some mutation-associated cellular abnormalities may be modifiable without deliberate DNA cutting.

But the work remains at an early experimental stage.

The findings do not establish a clinical treatment.

They do not apply to every genetic condition.

And they do not eliminate the substantial challenges associated with delivery, long-term safety, and biological specificity.

For Biotech International Institute, the broader lesson is compelling.

Sometimes the path toward a more precise intervention begins not by changing a molecule's identity, but by understanding how its activity is regulated.

The future of neurological medicine may involve multiple complementary strategies.

Small molecules.

Precision peptides.

Protein engineering.

Gene regulation.

And increasingly detailed human-relevant experimental models.

Each strategy has different strengths and limitations.

What unites responsible development is the need for evidence.

The question is not simply whether scientists can make a gene more active.

It is whether they can demonstrate that doing so produces a reproducible, appropriately controlled, safe, and meaningful biological benefit.

Mechanism First. Validation Always.

Biotech International Institute

Research-stage. Built for validation.

Science. People. Communities. A Healthier Tomorrow.

---

Scientific References

1. Chen, G. T., Nair, G., Osorio, A. J., et al. (2026).

Enhancer-targeted CRISPR-A rescues haploinsufficiency and mutant phenotypes in organoid models of autism.

Nature Neuroscience. Published November 13, 2026.

https://doi.org/10.1038/s41593-026-02504-9

2. UCLA Health (2026).

UCLA researchers discover new approach for treating autism and conditions caused by a single faulty gene copy.

November 13, 2026.

https://www.uclahealth.org/news/release/ucla-researchers-discover-new-approach-treating-autism-and

3. Related research

Large-scale discovery of neural enhancers for cis-regulation therapies.

Published research on CRISPR activation of neurodevelopmental genes, including CHD8 and SCN2A.

https://pubmed.ncbi.nlm.nih.gov/41278953/

Research disclosure: This article discusses independent, peer-reviewed laboratory research. The experiments involved human-derived neural cells and cortical organoids, not treatment of human patients. The approach has not been established as a safe or effective therapy for autism or other neurodevelopmental conditions. BII's neurological and peptide programs remain investigational. No direct activity involving CRISPR activation, CHD8, SCN2A, or clinical therapeutic benefit has been demonstrated for BII's candidates.

Next
Next

How Does the Human Brain Know When Its Predictions Are Wrong?